Adsett Roger 4

What Happened

• Roger Adsett, a director of Definium Therapeutics (DFTX), received two awards on June 11, 2026: 3,555 restricted stock units (RSUs) and a 14,620-share stock option award. Both awards are reported at $0.00 per share (i.e., they were grants, not purchases), so no cash was paid at grant.

Key Details

• Transaction date: June 11, 2026; Form 4 filed June 15, 2026 (after the transaction date).
• Awards: 3,555 RSUs (reported as A) and 14,620-share option award (reported as A, derivative).
• Price at grant: $0.00 per share (typical for compensation grants).
• Shares owned after transaction: Not disclosed in the provided filing.
• Footnotes: F1—Each RSU converts to one common share and vests 1/12th monthly; if the company’s first annual meeting after grant occurs before the first anniversary, unvested RSUs vest immediately before that meeting, subject to continued service. F2—The stock option vests 1/12th monthly with the same early-annual-meeting acceleration condition and requires continued service to vest.
• Filing timeliness: The Form 4 was filed four days after the grant date (June 11 → June 15), which is later than the typical two-business-day reporting window.

Context

• These were compensation grants (not sales or open-market purchases), which are routine director awards and do not by themselves signal buying or selling sentiment. The option is a derivative award that must vest monthly before it becomes exercisable; no exercise or sale occurred in this filing.